ZA200610050B - Treatment with oxaliplatin and an EGFR-inhibitor - Google Patents

Treatment with oxaliplatin and an EGFR-inhibitor

Info

Publication number
ZA200610050B
ZA200610050B ZA200610050A ZA200610050A ZA200610050B ZA 200610050 B ZA200610050 B ZA 200610050B ZA 200610050 A ZA200610050 A ZA 200610050A ZA 200610050 A ZA200610050 A ZA 200610050A ZA 200610050 B ZA200610050 B ZA 200610050B
Authority
ZA
South Africa
Prior art keywords
oxaliplatin
egfr
inhibitor
treatment
Prior art date
Application number
ZA200610050A
Other languages
English (en)
Inventor
Chen Jianping
Kolinsky Kenneth
Higgins Brian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200610050(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200610050B publication Critical patent/ZA200610050B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200610050A 2004-06-03 2006-11-30 Treatment with oxaliplatin and an EGFR-inhibitor ZA200610050B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57643504P 2004-06-03 2004-06-03

Publications (1)

Publication Number Publication Date
ZA200610050B true ZA200610050B (en) 2008-08-27

Family

ID=34970379

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610050A ZA200610050B (en) 2004-06-03 2006-11-30 Treatment with oxaliplatin and an EGFR-inhibitor

Country Status (17)

Country Link
US (1) US20050272738A1 (xx)
EP (1) EP1755622A1 (xx)
JP (1) JP2008501650A (xx)
KR (1) KR100881043B1 (xx)
CN (1) CN1960737A (xx)
AR (1) AR049135A1 (xx)
AU (1) AU2005249200A1 (xx)
BR (1) BRPI0511780A (xx)
CA (1) CA2566974A1 (xx)
IL (1) IL179367A0 (xx)
MX (1) MXPA06013997A (xx)
NO (1) NO20066057L (xx)
NZ (1) NZ551354A (xx)
RU (1) RU2006146623A (xx)
TW (1) TW200608959A (xx)
WO (1) WO2005117915A1 (xx)
ZA (1) ZA200610050B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117877A1 (en) * 2004-06-03 2005-12-15 F.Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
UA98665C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
UA98666C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
JP2014501918A (ja) * 2010-12-09 2014-01-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベバシズマブ併用療法のためのマーカーとしてのａｇｔｒ１
EP2890384B1 (en) * 2012-08-31 2021-11-03 TARIS Biomedical LLC Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201480A3 (en) * 1999-05-14 2009-03-30 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
AU5136100A (en) * 1999-05-17 2000-12-05 Avi Biopharma, Inc. Combined approach to treatment of cancer with hcg vaccines
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
EP1349574A2 (en) * 2001-01-09 2003-10-08 MERCK PATENT GmbH Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
JP2007501238A (ja) * 2003-08-01 2007-01-25 ワイス・ホールディングズ・コーポレイション 癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods

Also Published As

Publication number Publication date
MXPA06013997A (es) 2007-02-08
BRPI0511780A (pt) 2008-01-15
KR100881043B1 (ko) 2009-01-30
WO2005117915A1 (en) 2005-12-15
US20050272738A1 (en) 2005-12-08
AU2005249200A1 (en) 2005-12-15
CA2566974A1 (en) 2005-12-15
EP1755622A1 (en) 2007-02-28
IL179367A0 (en) 2007-03-08
JP2008501650A (ja) 2008-01-24
TW200608959A (en) 2006-03-16
CN1960737A (zh) 2007-05-09
NO20066057L (no) 2007-02-28
KR20070029185A (ko) 2007-03-13
AR049135A1 (es) 2006-06-28
NZ551354A (en) 2009-10-30
RU2006146623A (ru) 2008-07-20

Similar Documents

Publication Publication Date Title
IL179533A0 (en) Treatment with cisplatin and an egfr-inhibitor
IL179525A0 (en) Treatment with gemcitabine and an egfr-inhibitor
CA123330S (en) Electronic timer
EP1727498A4 (en) DEVICES AND METHODS FOR ENDOVASCULAR TREATMENT
IL185679A0 (en) Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes
CA117908S (en) Inhaler
IL228770A0 (en) processes and intermediates
PL375645A1 (pl) Zestaw elementu mocującego i wkrętaka, element mocujący i wkrętak do elementu mocującego
IL181670A0 (en) Substituted phenylaminothiazoles and use thereof
EP1824467A4 (en) APOGOSSYPOLON AND ITS USES
EP1786834A4 (en) IMPLANTABLE POWER SOURCES AND SENSORS
GB2435590B (en) An interleaver and associated methods
EP1723158A4 (en) O, O'-AMIDOMALONATE AND N, O-AMIDOMALONATE PLATINUM COMPLEXES
ZA200610052B (en) Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
IL177845A0 (en) Combination therapy with glatiramer acetate and riluzole
IL179497A0 (en) Carboranylporphyrins and uses thereof
EP1771263A4 (en) NARROW AERIAL CAMS AND MATRIX MOUNTED
EP1959029A4 (en) Palladium complex and catalyst-dispersing treatment solution therewith
GB0420022D0 (en) Fans and turbines
ZA200610050B (en) Treatment with oxaliplatin and an EGFR-inhibitor
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0420893D0 (en) Photosensitisers and their uses
CA115339S (en) Exercise apparatus
IL177759A0 (en) Cospeptin, cosmedin and their uses
EP1966842A4 (en) LIGHTING ELEMENTS, EQUIPMENT AND METHOD